Research Grade Faralimomab (HF565026)

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Interferon alpha/beta receptor 1 (beta receptor 1,Cytokine receptor family 2 member 1,Cytokine receptor class-II member 1,CRF2-1,IFN-R-1,IFNAR1,IFNAR,IFN-alpha/beta receptor 1,Type I interferon receptor 1) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes.